We have developed a magnetic resonance molecular imaging method using a novel
iron-oxide contrast agent targeted towards
P-selectin - MNP-PBP (magnetic nanoparticle-
P-selectin binding
peptide) - to image endothelial activation following
cerebral ischemia/reperfusion. MNP-PBP consists of approximately 1000 PBP
ligands (primary sequence: GSIQPRPQIHNDGDFEEIPEEYLQ GGSSLVSVLDLEPLDAAWL) conjugated to a 50 nm diameter aminated
dextran iron oxide particle. In vitro P- and
E-selectin binding was assessed by competition ELISA. Transient focal
cerebral ischemia was induced in male C57/BL 6 mice followed by contrast injection (MNP-PBP; MNP-NH2;
Feridex; MNP-PBP-
FITC) at 24 h after reperfusion and T(2) magnetic resonance imaging at 9.4 T was performed.
Infarction and microvasculature accumulation of
contrast agent was assessed in coronal brain sections. MNP-PBP attenuated antibody binding to
P-selectin by 34.8 +/- 1.7%.
P-selectin was preferentially increased in the
infarct hemisphere and MNP-PBP-
FITC accumulation in the
infarct hemisphere microvasculature was observed. Compared with the nontargeted
iron oxide agents MNP-NH2 and
Feridex, MNP-PBP showed a significantly greater T(2) effect within the
infarction. MR imaging of
P-selectin expression with a targeted iron oxide nanoparticle
contrast agent may reveal early endothelial activation in
stroke and other neuroinflammatory states.